Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ABSTRAL vs BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.
Partial mu-opioid receptor agonist (buprenorphine) and mu-opioid receptor antagonist (naloxone). Buprenorphine has high affinity but low intrinsic activity at mu receptors, producing ceiling effects on respiratory depression and euphoria. Naloxone antagonizes opioid effects and is poorly absorbed sublingually, added to discourage parenteral abuse.
Management of breakthrough pain in cancer patients aged 18 and older who are already receiving and tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain.
Treatment of opioid dependence (FDA-approved),Off-label: chronic pain (buprenorphine alone)
For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.
Sublingual: 2/0.5 mg to 4/1 mg once daily initially; titrate up to 8/2 mg, 12/3 mg, or 16/4 mg once daily; maximum 24/6 mg once daily. Buccal: 2.1/0.3 mg once daily initially; titrate up to 4.2/0.7 mg, 8.4/1.4 mg, or 12.6/2.1 mg once daily; maximum 12.6/2.1 mg once daily.
Terminal elimination half-life: 6-10 hours (mean 8 hours); prolonged in elderly and hepatic impairment
Buprenorphine: terminal half-life 24-60 hours (mean ~37 h) due to slow dissociation from opioid receptors; clinically relevant for once-daily or alternate-day dosing. Naloxone: terminal half-life 1-2 hours; rapid elimination limits oral systemic availability.
Hepatic metabolism primarily via CYP3A4; major metabolites include norfentanyl (inactive) and other minor metabolites.
Primarily via N-dealkylation by CYP3A4 to norbuprenorphine (active metabolite); also glucuronidation by UGT1A1, UGT2B7, UGT1A3. Naloxone is extensively metabolized in the liver, primarily by glucuronidation.
Renal: ~70% as metabolites (primarily fentanyl conjugates and norfentanyl), ~10% unchanged; Fecal: ~9%; Biliary: minimal
Buprenorphine: primarily fecal (69-70%) via biliary excretion; renal (10-30%) as unchanged drug and metabolites. Naloxone: extensively metabolized in liver, primarily conjugated; renal excretion of metabolites (70%), minimal unchanged (<1%).
80-85% bound primarily to albumin and alpha-1-acid glycoprotein
Buprenorphine: ~96% bound primarily to alpha- and beta-globulins, also to albumin. Naloxone: ~45% bound to plasma proteins (mainly albumin).
4-6 L/kg; large Vd indicates extensive tissue distribution
Buprenorphine: Vd ~3-5 L/kg; high due to lipophilicity and extensive tissue distribution. Naloxone: Vd ~2 L/kg; moderate distribution.
Sublingual: 70-90% (mean 80%); buccal: 50-65%; oral: ~30% due to first-pass metabolism
Sublingual buprenorphine: ~30-50% (range 15-70%). Oral buprenorphine: <10% due to first-pass metabolism. Sublingual naloxone: <2% due to extensive first-pass; negligible under normal conditions, but sufficient to precipitate withdrawal if injected.
No specific GFR-based dose adjustment recommended; use caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation of fentanyl.
No dose adjustment required for mild-moderate renal impairment (GFR >=30 m L/min). For severe renal impairment (GFR <30 m L/min), initiate with low doses and titrate cautiously; buprenorphine is highly protein bound but naloxone may accumulate.
For Child-Pugh Class A or B: no adjustment required; for Child-Pugh Class C: reduce dose and monitor closely for toxicity due to reduced clearance.
Child-Pugh A: no adjustment. Child-Pugh B: use lower initial doses (e.g., 2/0.5 mg sublingual) and titrate slowly. Child-Pugh C: contraindicated due to risk of accumulation and prolonged effects.
Not approved for pediatric patients <18 years; safety and efficacy not established.
Approved for ages >=16 years: dosing same as adults, but start at lowest possible dose (e.g., 2/0.5 mg sublingual) and titrate based on response. For <16 years: safety and efficacy not established.
Initiate at the lowest available dose (100 mcg) and titrate cautiously; elderly patients may have altered pharmacokinetics and increased sensitivity to fentanyl.
Use with caution; start at low end of dosing range (e.g., 2/0.5 mg sublingual) and titrate slowly due to increased sensitivity, risk of respiratory depression, falls, and cognitive impairment. Monitor renal and hepatic function.
Risk of respiratory depression, addiction, abuse, and misuse; risk of accidental ingestion; risk of medication errors resulting in fatal overdose; life-threatening respiratory depression in opioid-non-tolerant patients; risk of opioid analgesic drug interactions with CNS depressants; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
Risk of serious respiratory depression, especially during initiation or dose escalation. Concomitant use with CNS depressants (e.g., benzodiazepines, alcohol) may lead to profound sedation, respiratory depression, coma, and death. Neonatal opioid withdrawal syndrome may occur if used during pregnancy. Accidental ingestion, especially by children, can cause fatal respiratory depression.
Respiratory depression, QT prolongation, serotonin syndrome, adrenal insufficiency, severe hypotension, seizures, biliary tract disease, gastrointestinal obstruction, withdrawal syndrome, and risk of overdose with alcohol or other CNS depressants.
Risk of respiratory depression, misuse/abuse, dependence, and withdrawal if abruptly discontinued. Adrenal insufficiency, hepatotoxicity (rare), QTc prolongation (buprenorphine high doses), and precipitation of withdrawal if given too soon after full agonist opioids. Use caution in patients with hepatic impairment, biliary tract disease, or head injury.
Hypersensitivity to fentanyl or any components; opioid-non-tolerant patients; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; concurrent use of MAOIs or within 14 days of discontinuation.
Hypersensitivity to buprenorphine or naloxone. Significant respiratory depression. Acute or severe bronchial asthma. Known or suspected gastrointestinal obstruction. Concomitant use with MAOIs or within 14 days of MAOI use (relative).
Avoid grapefruit and grapefruit juice during treatment as they inhibit CYP3A4, increasing fentanyl exposure. No other significant food interactions; however, avoid alcohol due to additive CNS depressant effects. Maintain consistent meal timing relative to dosing to minimize variability.
No specific food interactions. Grapefruit juice may increase buprenorphine levels via CYP3A4 inhibition; avoid excessive consumption. Avoid alcohol-containing foods or beverages due to additive CNS depression.
FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in animal studies. Second trimester: No specific malformation risk. Third trimester: Prolonged use can cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth.
Pregnancy Category C. First trimester: Limited human data; animal studies show reduced fetal growth and increased fetal loss at high doses. Second and third trimesters: Chronic exposure may cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at delivery. Not associated with major malformations.
Minimal excretion into breast milk; M/P ratio not reported. Fentanyl is poorly absorbed orally, making significant infant exposure unlikely. Monitor infant for sedation, respiratory depression, and poor feeding. Avoid use in breastfeeding mothers with opioid dependence or high doses.
Buprenorphine is excreted in breast milk with an estimated average infant dose of 1-2% of maternal weight-adjusted dose. Naloxone has poor oral bioavailability. M/P ratio: buprenorphine ~0.6-1.0. Generally considered compatible with breastfeeding, but monitor infant for drowsiness, respiratory depression, and feeding difficulties.
Pregnancy increases clearance and volume of distribution, potentially reducing drug levels. Dose adjustments may be needed: initiate with lower doses and titrate to effect; consider increasing frequency or using breakthrough doses. Monitor for inadequate analgesia. Avoid abrupt discontinuation; taper if stopping.
No standard dose adjustment required in pregnancy, but pharmacokinetic changes (increased clearance, volume of distribution) may necessitate splitting total daily dose into 3-4 doses to avoid withdrawal symptoms. Individualize based on clinical response and signs of withdrawal.
ABSTRAL (fentanyl sublingual spray) is a transmucosal immediate-release fentanyl (TIRF) formulation indicated for breakthrough pain in opioid-tolerant patients. Due to high bioavailability (~70%) and rapid onset (peak plasma concentration at 15-30 minutes), initial titration must start with 100 mcg, with dose escalation based on efficacy and tolerability. Weight-based conversion from other fentanyl products is not valid; utilize the provided conversion table. Patients must have a rescue agent (e.g., naloxone) available. Concomitant use with CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) or inducers (e.g., rifampin, carbamazepine) requires dose adjustment. Avoid use in opioid-naïve patients due to risk of respiratory depression.
Buprenorphine/naloxone is a partial mu-opioid agonist with a ceiling effect on respiratory depression, reducing abuse potential but requiring careful induction in opioid-dependent patients to avoid precipitated withdrawal. Sublingual administration bypasses first-pass metabolism; naloxone has poor sublingual bioavailability but precipitates withdrawal if injected parenterally. Monitor hepatic function due to rare hepatotoxicity. Avoid use in severe hepatic impairment. The combination is preferred over buprenorphine alone to deter diversion. Dose adjustments may be needed in renal impairment. Pregnancy: not recommended unless benefit outweighs risk; can cause neonatal opioid withdrawal syndrome.
Use only for breakthrough cancer pain while on around-the-clock opioid therapy.,Do not switch from other fentanyl products based on dose; follow specific conversion instructions.,Spray entire dose into mouth; do not swallow or rinse for at least 10 minutes.,Store at room temperature, away from children and pets.,Dispose of unused units via drug take-back program or by flushing down toilet per FDA guidelines.,Never share this medication with others; death may occur.,Seek emergency if severe drowsiness, confusion, or slow breathing occurs.
Take this medication exactly as prescribed under the tongue; do not chew or swallow it.,Do not inject or snort the medication; this can cause severe withdrawal or overdose.,Avoid alcohol and other central nervous system depressants (e.g., benzodiazepines) as they increase risk of respiratory depression.,Store the medication securely and out of reach of children; properly dispose of unused medication via a take-back program.,Do not stop abruptly; withdrawal symptoms may occur. Follow your provider's tapering plan.,Inform all healthcare providers that you are taking this medication.,Seek emergency care if you experience difficulty breathing, severe drowsiness, or signs of allergic reaction.,This medication is part of a comprehensive treatment plan including counseling and behavioral therapy.
No interactions on record
"Cobicistat is a potent CYP3A4 inhibitor used to boost the pharmacokinetics of antiretroviral agents like atazanavir and darunavir. Naloxone primarily undergoes glucuronidation via UGT1A6 and UGT2B7, with minor CYP3A4 metabolism. Concomitant use with Cobicistat may modestly increase naloxone exposure due to CYP3A4 inhibition, but this is unlikely to be clinically significant given naloxone's wide therapeutic index and short half-life."
"Fluvoxamine, a selective serotonin reuptake inhibitor (SSRI), is primarily metabolized by cytochrome P450 (CYP) 1A2 and 2D6. Naloxone, an opioid antagonist, is reported to inhibit CYP1A2, potentially decreasing the clearance of fluvoxamine. This interaction may lead to increased fluvoxamine plasma concentrations, elevating the risk of serotonin syndrome, QT prolongation, and other dose-dependent adverse effects, especially in patients receiving high doses or those with hepatic impairment."
"Naloxone, an opioid receptor antagonist, may inhibit the cytochrome P450 isoenzyme CYP3A4, which is responsible for the metabolism of ivacaftor. Concomitant administration can lead to reduced clearance of ivacaftor, resulting in elevated serum concentrations. This increase may potentiate the therapeutic effects and adverse reactions of ivacaftor, such as hepatotoxicity and QT prolongation."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ABSTRAL vs BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE, answered by our medical review team.
ABSTRAL is a Opioid Analgesic that works by Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.. BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE is a Opioid Antagonist that works by Partial mu-opioid receptor agonist (buprenorphine) and mu-opioid receptor antagonist (naloxone). Buprenorphine has high affinity but low intrinsic activity at mu receptors, producing ceiling effects on respiratory depression and euphoria. Naloxone antagonizes opioid effects and is poorly absorbed sublingually, added to discourage parenteral abuse.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ABSTRAL and BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ABSTRAL is: For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.. The standard adult dose of BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE is: Sublingual: 2/0.5 mg to 4/1 mg once daily initially; titrate up to 8/2 mg, 12/3 mg, or 16/4 mg once daily; maximum 24/6 mg once daily. Buccal: 2.1/0.3 mg once daily initially; titrate up to 4.2/0.7 mg, 8.4/1.4 mg, or 12.6/2.1 mg once daily; maximum 12.6/2.1 mg once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ABSTRAL and BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ABSTRAL is classified as Category C. FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in a. BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE is classified as Category A/B. Pregnancy Category C. First trimester: Limited human data; animal studies show reduced fetal growth and increased fetal loss at high doses. Second and third trimesters: Chronic exp. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.